DCT

1:26-cv-07949

Incyte Corp v. MSN Pharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-07949, D.N.J., 06/30/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant MSN Pharmaceuticals Inc. maintains a regular and established physical place of business in the district, and both defendants have taken steps to market and sell the accused products in the district by filing an Abbreviated New Drug Application (ANDA) with the FDA.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an ANDA to the FDA seeking approval to market a generic version of Plaintiff's Jakafi® (ruxolitinib) tablets constitutes an act of infringement of six U.S. patents related to the ruxolitinib compound, its salts, and methods of use.
  • Technical Context: The technology relates to small molecule inhibitors of Janus kinases (JAKs), a family of enzymes involved in immune system signaling pathways that are implicated in myeloproliferative neoplasms, inflammatory diseases, and cancer.
  • Key Procedural History: The lawsuit was triggered under the Hatch-Waxman Act by Defendants' submission of ANDA No. 221086, which included a "Paragraph IV Certification" alleging that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic product. The patents are listed in the FDA's "Orange Book" as covering Incyte's approved Jakafi® drug.

Case Timeline

Date Event
2005-11-16 Priority Date for '257' and '362' Patents
2007-01-12 Priority Date for '693', '481', '013', and '429' Patents
2009-10-06 Issue Date for U.S. Patent No. 7,598,257
2013-04-09 Issue Date for U.S. Patent No. 8,415,362
2014-05-13 Issue Date for U.S. Patent No. 8,722,693
2014-09-02 Issue Date for U.S. Patent No. 8,822,481
2014-09-09 Issue Date for U.S. Patent No. 8,829,013
2018-07-10 Issue Date for U.S. Patent No. 10,016,429
2026-06-30 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,598,257 - "Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors"

The Invention Explained

  • Problem Addressed: The patent identifies a need for new therapeutic agents that can modulate the activity of protein kinases (PKs), specifically the Janus kinase (JAK) family of enzymes (e.g., JAK1, JAK2, JAK3) (Compl. Ex. A, col. 1:16-19). Abnormal JAK activity is associated with a variety of diseases, including immune-related disorders, myeloproliferative disorders, and cancer (Compl. Ex. A, col. 4:1-12).
  • The Patented Solution: The patent discloses a genus of chemical compounds, characterized by a heteroaryl-substituted pyrrolo[2,3-b]pyridine or pyrrolo[2,3-b]pyrimidine core structure, that are designed to inhibit the activity of JAKs (Compl. Ex. A, abstract; Compl. Ex. A, col. 6:8-23). By inhibiting these enzymes, the compounds are intended to treat the associated diseases (Compl. Ex. A, col. 6:19-23).
  • Technical Importance: The invention provided a new class of chemical entities for targeting the JAK signaling pathway, a key therapeutic target for a range of immunological and oncological conditions (Compl. Ex. A, col. 5:4-10).

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the '257' patent without specifying which ones (Compl. ¶ 36). Independent claim 1 is representative of the core invention.
  • Independent Claim 1 claims:
    • A compound of a specific chemical structure, Formula I, based on a pyrrolo[2,3-b]pyrimidine core.
    • The formula includes multiple variable substituents (A¹, A², U, V, Y, Z, R¹, R²) which are defined by extensive Markush groups, covering a large number of related chemical structures.
    • The claim also covers pharmaceutically acceptable salts of these compounds.
  • The complaint reserves the right to assert other claims, including dependent claims.

U.S. Patent No. 8,415,362 - "Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors"

The Invention Explained

  • Problem Addressed: Similar to the '257' patent, this patent addresses the need for compounds capable of modulating the activity of JAK enzymes to treat related diseases (Compl. Ex. B, col. 1:16-24).
  • The Patented Solution: The patent claims a specific chemical entity, ruxolitinib, identified by its chemical name (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, and its pharmaceutically acceptable salts (Compl. Ex. B, abstract; Compl. Ex. B, col. 387:41-44). This compound is a specific species that falls within the broader genus described in the '257' patent.
  • Technical Importance: The identification of this specific compound, ruxolitinib, represented a significant step in developing a clinically viable and potent JAK inhibitor, which became the active ingredient in the drug Jakafi®.

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the '362' patent (Compl. ¶ 45). Independent claim 1 is central to the dispute.
  • Independent Claim 1 claims:
    • The specific compound "(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile."
    • Or a pharmaceutically acceptable salt thereof.
  • The complaint reserves the right to assert other claims.

U.S. Patent No. 8,722,693 - "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile"

  • Patent Identification: U.S. Patent No. 8,722,693, "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile," issued May 13, 2014 (Compl. ¶ 10).
  • Technology Synopsis: This patent addresses the need for improved forms of the ruxolitinib compound for pharmaceutical use (Compl. Ex. C, col. 2:1-5). It discloses and claims specific salt forms of ruxolitinib, including the phosphate salt, which may possess advantageous properties such as crystallinity, stability, or solubility compared to the free base form (Compl. Ex. C, abstract; Compl. Ex. C, col. 2:13-24).
  • Asserted Claims: The complaint asserts one or more claims (Compl. ¶ 54). Independent claims include Claim 1 (the phosphate salt of ruxolitinib) and Claim 8 (a pharmaceutical composition comprising the phosphate salt).
  • Accused Features: Defendants' proposed generic ruxolitinib drug product, which is alleged to be or contain the claimed phosphate salt of ruxolitinib (Compl. ¶ 1; Compl. ¶ 54).

U.S. Patent No. 8,822,481 - "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile"

  • Patent Identification: U.S. Patent No. 8,822,481, "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile," issued September 2, 2014 (Compl. ¶ 11).
  • Technology Synopsis: This patent claims specific crystalline forms (polymorphs) of the phosphate salt of ruxolitinib, as well as methods of treatment using this crystalline salt (Compl. Ex. D, abstract). Different crystalline forms of a drug can have different physical properties that affect manufacturing and therapeutic performance, making them independently patentable subject matter (Compl. Ex. D, col. 3:1-12).
  • Asserted Claims: The complaint asserts one or more claims (Compl. ¶ 63). Independent claims include Claim 1 (a method of treating a myeloproliferative disorder), Claim 8 (a specific crystalline ruxolitinib phosphate salt), Claim 15 (a pharmaceutical composition), and Claim 22 (a method of modulating JAK activity).
  • Accused Features: Defendants' proposed generic drug product is alleged to be the claimed crystalline salt and to be used in a manner that infringes the method claims (Compl. ¶ 1; Compl. ¶ 63).

U.S. Patent No. 8,829,013 - "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile"

  • Patent Identification: U.S. Patent No. 8,829,013, "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile," issued September 9, 2014 (Compl. ¶ 12).
  • Technology Synopsis: Following the same strategy as the '693' and '481' patents, this patent claims a different salt form of ruxolitinib: the maleic acid salt (Compl. Ex. E, abstract). The invention provides an alternative salt form with potentially useful pharmaceutical properties (Compl. Ex. E, col. 2:3-12).
  • Asserted Claims: The complaint asserts one or more claims (Compl. ¶ 72). Independent claims are Claim 1 (the maleate salt of ruxolitinib) and Claim 5 (a pharmaceutical composition containing the maleate salt).
  • Accused Features: Defendants' proposed generic ruxolitinib drug product is alleged to be or contain the claimed maleate salt of ruxolitinib (Compl. ¶ 1; Compl. ¶ 72).

U.S. Patent No. 10,016,429 - "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile"

  • Patent Identification: U.S. Patent No. 10,016,429, "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile," issued July 10, 2018 (Compl. ¶ 13).
  • Technology Synopsis: This patent claims methods of using a salt of ruxolitinib, specifically the phosphate salt, for treating a particular medical condition: graft-versus-host disease (GVHD) (Compl. Ex. F, abstract). This is a method-of-use patent that protects a specific therapeutic application of the drug (Compl. Ex. F, col. 12:14-20).
  • Asserted Claims: The complaint asserts one or more claims (Compl. ¶ 81). Independent claims are Claim 1 (a method of treating GVHD in a patient in need thereof) and Claim 6 (also a method of treating GVHD with a pharmaceutical composition).
  • Accused Features: The accused instrumentality is the submission of the ANDA itself, which seeks approval for a product whose label will allegedly instruct for the treatment of GVHD, thereby inducing infringement of the claimed methods (Compl. ¶ 32; Compl. ¶ 81).

III. The Accused Instrumentality

Product Identification

The accused products are the generic ruxolitinib tablets (5 mg, 10 mg, 15 mg, 20 mg, and 25 mg) that are the subject of Defendants' ANDA No. 221086 ("MSN's Proposed Products") (Compl. ¶ 1; Compl. ¶ 22).

Functionality and Market Context

The filing of the ANDA is a statutorily-defined act of infringement under 35 U.S.C. § 271(e)(2) (Compl. ¶ 36). This provision allows patent holders to litigate their rights before a generic drug enters the market. Defendants seek FDA approval to manufacture and sell their generic products in the United States prior to the expiration of the patents-in-suit (Compl. ¶ 1). The complaint alleges that the labeling for MSN's Proposed Products will instruct physicians and patients to administer the drug for indications covered by the asserted patents, including methods of treatment (Compl. ¶ 32).

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element infringement analysis or claim chart exhibit. The infringement allegations are premised on the statutory act of infringement created by 35 U.S.C. § 271(e)(2), where the submission of an ANDA for a drug claimed in a patent or for a use claimed in a patent is an act of infringement. No probative visual evidence provided in complaint.

'257 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of Formula I... or a pharmaceutically acceptable salt thereof... The complaint alleges that the ruxolitinib active ingredient in MSN's Proposed Products is a compound covered by the chemical genus of Formula I. ¶36 col. 6:8-23

'362 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof. The complaint alleges that the active ingredient in MSN's Proposed Products is ruxolitinib, the specific compound identified in Claim 1. ¶45 col. 387:41-44

Identified Points of Contention

  • Structural and Compositional Scope: For the compound ('257', '362') and salt ('693', '481', '013') patents, the primary question for infringement will be whether the chemical composition of MSN's Proposed Products falls within the scope of the claims. In a typical ANDA case, the generic manufacturer seeks to market a bioequivalent drug, suggesting the active ingredient is identical. The dispute may therefore center on whether MSN uses the specific salt forms or polymorphs claimed in the '693', '481', and '013' patents.
  • Validity: The core of the dispute will likely be the validity of the patents-in-suit. Defendants' Paragraph IV certification asserts that the patents are invalid and/or not infringed (Compl. ¶ 33). This raises the question of whether the claimed inventions would have been obvious over or anticipated by the prior art at the time of filing.
  • Method of Use: For the method-of-use claims ('429' patent), a key question will be whether the proposed label for MSN's product will instruct users to perform the patented method of treating GVHD, thereby supporting a claim for induced infringement.

V. Key Claim Terms for Construction

  • The Term: "pharmaceutically acceptable salt" (from Claim 1 of the '257' and '362' Patents, and related terms in the '693', '481', '013', and '429' patents)
  • Context and Importance: The definition of this term is critical because the specific salt form of an active pharmaceutical ingredient can impact its patentability and infringement profile. If MSN's product uses a different salt of ruxolitinib than Incyte's, the scope of this term will determine whether it still infringes claims covering the base compound "or a pharmaceutically acceptable salt thereof."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The '257' patent specification provides a broad, exemplary definition, stating the term "is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein" and provides a long, non-exhaustive list of examples (Compl. Ex. A, col. 32:27-67).
    • Evidence for a Narrower Interpretation: A party could argue that subsequent patents in the family, which specifically claim phosphate ('693', '481') and maleate ('013') salts, suggest that these specific salts were considered distinct inventions from the general concept of a "pharmaceutically acceptable salt" in the earlier patents.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval of its ANDA, MSN will induce infringement of the patents-in-suit (Compl. ¶ 39; Compl. ¶ 48; Compl. ¶ 57; Compl. ¶ 66; Compl. ¶ 75; Compl. ¶ 84). The basis for this allegation is that MSN's proposed product labeling will instruct and encourage medical professionals and patients to use the generic drug in accordance with the patented methods (Compl. ¶ 32).
  • Willful Infringement: While the complaint does not use the word "willful," it requests a finding that the case is "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 (Compl. ¶ 42; Compl. ¶ 52; Compl. ¶ 61; Compl. ¶ 70; Compl. ¶ 78; Compl. ¶ 88). It also alleges that MSN's infringement will be intentional upon approval, given its knowledge of the patents (e.g., Compl. ¶ 39). This provides a basis for enhanced damages if infringement is found post-suit.

VII. Analyst’s Conclusion: Key Questions for the Case

  1. Validity of the Ruxolitinib Compound Patents: A primary issue will be one of validity: can Defendants demonstrate with clear and convincing evidence that the broad genus claim of the '257' patent or the specific ruxolitinib compound claim of the '362' patent were anticipated or rendered obvious by prior art available before the November 2005 priority date?
  2. Infringement and Validity of the Salt/Polymorph Patents: The case will likely involve a significant dispute over composition and patentability of form. First, does the active ingredient in MSN's proposed product meet the specific limitations of the claimed phosphate ('693', '481') or maleate ('013') salts, including specific crystalline forms? Second, even if it does, are those salt and polymorph claims valid inventions or merely obvious modifications of the known ruxolitinib compound?
  3. Induced Infringement via Drug Label: A central question for the method-of-use patent ('429') will be one of inducement: does the language in the proposed label for MSN's generic product actively instruct or encourage physicians to prescribe the drug for the treatment of graft-versus-host disease, thereby creating liability for induced infringement?
Loading Complaint